Anthony Petrone’s rating is based on several promising developments regarding LivaNova’s OSPREY study for treating obstructive sleep apnea (OSA). The company announced favorable 6-month results from ...

Needham analyst Michael Matson has maintained their bullish stance on LIVN stock, giving a Buy rating on October 31. Michael Matson has given ...

LivaNova met the primary endpoints for its OSPREY trial, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation.

LivaNova today announced that its OSPREY trial of nerve stimulation for treating sleep apnea met its primary endpoints.

1 of 1' marketing platform, and our commitment to our... LivaNova PLC , a market-leading medical technology company, today announced that it met the primary endpoints for its OSPREY randomized ...

Nov. 12, 2024 — Researchers have found that the way DNA is packaged in cells can directly impact how fast DNA itself is copied during cell division. They discovered that DNA packaging sends ...

A team of AI researchers and mathematicians affiliated with several institutions in the U.S. and the U.K. has developed a math benchmark that allows scientists to test the ability of AI systems to ...

Mizuho analyst Anthony Petrone lowered the firm’s price target on LivaNova (LIVN) to $70 from $80 and keeps an Outperform rating on the shares following the Q3 report. The firm still sees $4 in ...

Q3 2024 Earnings Call Transcript October 30, 2024 LivaNova PLC misses on earnings expectations. Reported EPS is $0.604 EPS, ...

LivaNova PLC (NASDAQ:LIVN), is not the largest company out there, but it saw a double-digit share price rise of over 10% in the past couple of months on the NASDAQGS. Shareholders may appreciate ...

Welcome to LivaNova's conference call for the third ... In OSA, we are encouraged by the early stoppage in enrollment of the OSPREY study in March, which was based on a determination that there ...